OAM
ALNY icon

Ostrum Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ostrum Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$538K Buy
1,788
+827
+86% +$249K 0.03% 313
2026
Q1 		$318K Buy
961
+14
+1% +$4.76K 0.02% 409
2025
Q4 		$377K Buy
947
+566
+149% +$250K 0.02% 406
2025
Q3 		$174K Sell
381
-13
-3% -$5.29K 0.01% 501
2025
Q2 		$128K Sell
394
-12
-3% -$3.32K 0.01% 529
2025
Q1 		$110K Sell
406
-11
-3% -$2.83K 0.01% 563
2024
Q4 		$98.1K Sell
417
-3,986
-91% -$1.05M 0.01% 592
2024
Q3 		$1.21M Sell
4,403
-1,339
-23% -$349K 0.1% 281
2024
Q2 		$1.4M Sell
5,742
-447
-7% -$70.6K 0.12% 256
2024
Q1 		$925K Hold
6,189
– – 0.07% 356
2023
Q4 		$1.18M Buy
6,189
+5,734
+1,260% +$977K 0.1% 283
2023
Q3 		$80.6K Sell
455
-4
-0.9% -$763 0.01% 641
2023
Q2 		$87.2K Buy
459
+1
+0.2% +$198 0.01% 617
2023
Q1 		$91.7K Buy
+458
New +$96.3K 0.01% 603
2019
Q1 		– Sell
-4,219
Closed -$308K – 145
2018
Q4 		$308K Buy
+4,219
New +$325K 0.12% 144

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ostrum Asset Management's ALNY Position: Q2 2026 in Review

Ostrum Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 86% in Q2 2026, buying an estimated $249K and bringing the position to 1,788 shares worth $538K. The position accounts for 0.03% of the portfolio, ranked #313.

Ostrum Asset Management first reported a position in ALNY in Q4 2018 and has held it in 15 quarters since. The position peaked at $1.4M in Q2 2024. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Ostrum Asset Management held 1,788 shares of Alnylam Pharmaceuticals worth $538K as of Q2 2026.
  • Ostrum Asset Management bought 827 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $249K.
  • Alnylam Pharmaceuticals made up 0.03% of Ostrum Asset Management's portfolio in Q2 2026, its #313 holding.
  • Ostrum Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2018 and has held it in 15 quarters since.
  • Ostrum Asset Management's Alnylam Pharmaceuticals position peaked at $1.4M in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Ostrum Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.